# Julian Adams

Source: https://onco.cc/people/julian-adams/  
OnCo record `julian-adams` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Medicinal chemist who led the discovery of the proteasome inhibitor bortezomib and now heads Stand Up To Cancer as President and CEO.

## Summary

Julian Adams, PhD, is President and CEO of Stand Up To Cancer, the US charity that funds collaborative 'Dream Team' cancer research. A drug-discovery scientist, he led the development of the proteasome inhibitor bortezomib (Velcade), a cornerstone therapy in multiple myeloma. He joined SU2C in July 2023 and was subsequently promoted to President and CEO, according to the organisation's leadership page.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: leadership; drug development; research funding
- Role: President and CEO
- Specialisms: Drug discovery; Proteasome inhibitors; Multiple myeloma; Research funding

## Sources

- Society page: https://standuptocancer.org/about-us/leadership/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Adams+J%5BAuthor%5D+AND+proteasome

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- institutions: [Stand Up To Cancer](https://onco.cc/institutions/stand-up-to-cancer/)
- journals: [Cancer investigation](https://onco.cc/journals/cancer-investigation/), [The oncologist](https://onco.cc/journals/the-oncologist/)

---
JSON: https://onco.cc/api/v1/entities/julian-adams.json